EAGLE-eyed reanalysis clarifies cognitive benefits of BioLineRx's schizophrenia contender
This article was originally published in Scrip
Executive Summary
An unnamed third party reviewed Phase IIb clinical trial results for the schizophrenia drug candidate BL-1020 and found that the BioLineRx antipsychotic significantly improved cognitive impairment more than the Israeli company revealed in its own analysis first published in 2009.